CML

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Retrieved on: 
목요일, 4월 11, 2024
Patient, BCR, Safety, MMR, TKI, CML, Caregiver, Second generation, Therapy, Acute leukemia, Pharmaceutical industry

BOULDER, Colo., April 11, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs) (NCT05304377).

Key Points: 
  • "Similar to our experience with previous successful Phase 1 trials in CML, ELVN-001 looks promising.
  • The preliminary data support that ELVN-001 is a potent and highly selective BCR::ABL1 inhibitor that has activity in heavily pre-treated patients, including post-asciminib patients."
  • “We are thrilled with ELVN-001’s initial Phase 1 data in heavily pre-treated patients with CML,” said Sam Kintz, Co-founder and Chief Executive Officer of Enliven.
  • The discussion will cover details of ELVN-001’s Phase 1 initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Retrieved on: 
수요일, 4월 10, 2024
University, Ipsen, Obesity, Novartis, IPO, Therapy, Pfizer, CML, Head, Biology, Biogen, Sangamo Therapeutics, Growth, Pharmaceutical industry

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.

Key Points: 
  • FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
  • “We are excited to welcome Melita to the Terns leadership team at a critical stage of growth at the company,” said Amy Burroughs, chief executive officer of Terns.
  • Most recently, she served as chief business officer at Structure Therapeutics, where she was responsible for the company’s business strategy, partnering initiatives, commercial planning, corporate branding and communications.
  • Previously, Ms. Jung served as senior vice president and head of business development at Sangamo Therapeutics, a genomic medicines company.

Cousins Maine Lobster Celebrates 12th Year Anniversary & 65th Unit Opening with Expansion into Northern Illinois!

Retrieved on: 
화요일, 4월 23, 2024
Restaurant, Multimedia, Food, FDD, CML, Franchise disclosure document

The expansion is led by brothers and franchisees, Yunus, and Thameem Shahul, who are in their 6th year franchising with Cousins Maine Lobster.

Key Points: 
  • The expansion is led by brothers and franchisees, Yunus, and Thameem Shahul, who are in their 6th year franchising with Cousins Maine Lobster.
  • The Northern Illinois truck marks the Shahul's 11th CML food truck to date.
  • This represents a major achievement as we expand our outreach to engage with dynamic communities of suburban Chicago on a more consistent basis.
  • Cousins Maine Lobster has food trucks and restaurants across the U.S., with additional new units planned this year.

Cousins Maine Lobster Celebrates 12th Year Anniversary & 65th Unit Opening with Expansion into Rhode Island!

Retrieved on: 
화요일, 4월 23, 2024
Restaurant, Multimedia, FDD, Seafood, Learning, CML, Franchise disclosure document, Food

The new truck will service all of Rhode Island, as well as Windham and New London counties in eastern Connecticut.

Key Points: 
  • The new truck will service all of Rhode Island, as well as Windham and New London counties in eastern Connecticut.
  • When asked about the expansion, Tara Nelson shared, "We can't wait to bring Cousins Maine Lobster to the Rhode Island market and beyond.
  • Cousins Maine Lobster is the perfect addition to the local food truck scene, and we are excited to serve all our hungry customers."
  • Cousins Maine Lobster has food trucks and restaurants across the U.S., with more than 20 new units planned in the coming year.

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Retrieved on: 
화요일, 4월 9, 2024
Acute leukemia, Canadian Aviation Regulations, Cell, CD33, AML, Patient, Tissue, CML, Acute myeloid leukemia, Leukemia, Death, AACR, Neoplasm, Cancer, Safety, CD123, Antigen, Vaccine

NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.

Key Points: 
  • The data was presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024 on April 9, 2024.
  • IN8bio's nsCAR platform is based on the natural ability of gamma-delta T cells to distinguish between healthy and malignant tissue.
  • Approved CAR-T therapies have shown remarkable efficacy against B cell malignancies, offering hope to patients with limited treatment options.
  • “These results can potentially improve INB-300, as we advance towards IND enabling studies of our next-generation gamma-delta T cell therapies to treat cancers.”

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Retrieved on: 
목요일, 3월 28, 2024
Patient, BCR, Acute leukemia, CML, Therapy, ATP, Pharmaceutical industry

ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.

Key Points: 
  • ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape.
  • ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.
  • The discussion will cover ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.
  • The event will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/ .

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Retrieved on: 
수요일, 3월 27, 2024
Research, Malignancy, Absorption, PD, CSF, Imatinib, Central nervous system, International, Patient, Gastrointestinal tract, Journal, CML, NDA, Pharmacist, Traffic barrier, Cerebrospinal fluid, Insurance, D&O, Dark Ages, Therapy, Division, Blood, Bone marrow, FDA, SAD, Physician, Approximation error, Pharmaceutical industry

The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.

Key Points: 
  • The Meeting Minutes confirmed that the 505(b)(2) pathway appears to be appropriate for approval of IkT-001Pro.
  • Inhibikase will host a conference call and webcast to discuss its full-year 2023 financial results and business highlights tomorrow, March 28, 2024, at 8:00am ET.
  • The conference call can be accessed by dialing 1-877-407-0789 (United States) or 1-201-689-8562 (International) and referencing Inhibikase Therapeutics.
  • After the live webcast, the event will be archived on Inhibikase’s website for approximately 90 days after the call.

Cousins Maine Lobster Celebrates Harrisburg Expansion, Grand Opening of Second Truck

Retrieved on: 
화요일, 4월 9, 2024
Growth, CML, FDD, Golden Joystick Awards, Franchise disclosure document, Multimedia, Lobster

SOUTH PORTLAND, Maine, April 9, 2024 /PRNewswire/ -- Cousins Maine Lobster announces the launch of their second food truck in Harrisburg, PA, further expanding their reach across Northeast and Central PA.

Key Points: 
  • SOUTH PORTLAND, Maine, April 9, 2024 /PRNewswire/ -- Cousins Maine Lobster announces the launch of their second food truck in Harrisburg, PA, further expanding their reach across Northeast and Central PA.
  • The Grand Opening of the second truck, led by husband-and-wife franchisees Cindy and Peter Sztankovits, will take place on Saturday, April 13th, at New Trail Brewing in Williamsport, PA.
  • Customers have traveled from all over Pennsylvania to enjoy Cousins Maine Lobster, fueling the opening of the second truck in Harrisburg.
  • Cousins Maine Lobster – Harrisburg, PA Truck Two Grand Opening Celebration
    Cousins Maine Lobster is seeking new franchisees nationwide.

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Retrieved on: 
화요일, 3월 19, 2024
HER2, Acute leukemia, Exercise, Index, Exchange, Colorectal cancer, MMR, Memorial, Headache, Patient, Research, Diarrhea, Brain, CML, KOL, Aes, Sale, Cancer, Security (finance), IND, MBA, Prospectus, MBC, Nausea, Therapy, CRC, PIPE, Pharmacokinetics, MTD, Food, Pharmaceutical industry

BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.

Key Points: 
  • “The additional funding further strengthens our balance sheet and enables us to achieve critical, longer-term clinical milestones as we advance our parallel lead programs, ELVN-001 and ELVN-002.
  • Enliven anticipates the gross proceeds from the private placement to be approximately $90 million, before deducting offering expenses.
  • The PIPE financing is expected to close on or about March 21, 2024, subject to satisfaction of customary closing conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Retrieved on: 
목요일, 3월 14, 2024
Pharmacokinetics, Patient, Administration, Research and development, Weight loss, Obesity, BCR-ABL, CML, GIPR, Safety, Pharmaceutical industry

FOSTER CITY, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $17.5 million and $63.5 million for the quarter and year ended December 31, 2023, respectively, as compared with $10.7 million and $39.6 million for the quarter and year ended December 31, 2022, respectively.
  • General and Administrative (G&A) Expenses: G&A expenses were $6.6 million and $39.1 million for the quarter and year ended December 31, 2023, respectively, as compared with $6.2 million and $22.4 million for the quarter and year ended December 31, 2022, respectively.
  • Net Loss: Net loss was $21.0 million and $90.2 million for the quarter and year ended December 31, 2023, respectively, as compared with $15.8 million and $60.3 million for the quarter and year ended December 31, 2022, respectively.